Aussie medtech forges ahead, making inroads with new technology

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) PharmaQC to Thermo Fisher Scientific. This milestone marks a noteworthy achievement for the company, showcasing its expansion in the medical technology sector.

The potential benefits of the system is substantial, with the promise of streamlining quality control processes and improving the reliability and safety of pharmaceutical products. The move follows a surge in market interest from pharmaceutical customers, a testament to the success of LBT Innovations’ market development activities undertaken in the latter half of the calendar year 2023. Notably, this accomplishment comes approximately six months ahead of initial expectations.

What sets APAS PharmaQC apart is its distinction as the sole artificial intelligence technology for automated culture plate reading to have received clearance from the United States Food and Drug Administration (FDA).

As part of a strategic development partnership with Thermo Fisher, LBT Innovations finalised the sale of the instrument, providing essential funding for the ongoing development of APAS PharmaQC. The system is designed to support culture plate media utilised in pharmaceutical microbial quality control applications.

Brent Barnes, CEO and Managing Director of LBT Innovations, expressed the significance of this achievement, stating, “This is an important milestone for the Company, being the first deployment of APAS PharmaQC outside of our partnership with AstraZeneca. The evaluation performed by Thermo Fisher will provide meaningful performance data supporting ‘real-world’ use of our technology. This will provide a further third-party validation of APAS PharmaQC and further enhance our commercial activation of the product.”

The company’s focus on research and development has received backing from MTPConnect through the BioMedTech Horizons (BMTH) accelerator program. This support plays a crucial role in transforming innovative ideas into tangible, homegrown medical products, contributing to the development of critical sovereign manufacturing capabilities.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.